Welcome to Avanir’s Fiscal 2012 Interactive Annual Report.
We invite you to explore the following pages to find out more about our achievements over the last 12 months.

CEO Letter

Building a sustainable biopharmaceutical business designed to provide innovative new therapies to patients with high unmet need.

Read > >

Nuedexta

The first and only medication FDA approved to treat Pseudobulbar Affect.

Read > >

Pipeline

A robust pipeline - a number of indications that we believe our CNS platform can address.

Read > >

Financials

A strong balance sheet and growing revenues

Read > >